. Author manuscript; available in PMC: 2016 Oct 21.

Published in final edited form as: Nephron. 2015 Oct 21;131(3):191–201. doi: 10.1159/000441151

Table 3.

Multivariate mixed linear regression model examining the association between change in MAP and change in serum creatinine in the norepinephrine cohort.

Presumed HRS Cohort (n=14)^a,^b

Effect	Beta Estimate	Error	DF	T value	P-Value
Intercept	−3.587	2.231	10	−1.61	0.14
MAP change	−0.042	0.013	33	−3.20	0.002
sCr baseline	0.302	0.144	33	2.10	0.04
MAP baseline	0.039	0.024	33	1.60	0.12
Day of therapy	−0.144	0.144	13	−1.00	0.34
MELD score	−0.005	0.031	33	−0.15	0.88

Includes those who failed midodrine/octreotide prior to receiving norepinephrine (n=10) and those who were treated de novo (n=4).

Six out of the 14 patients qualified as Definite HRS.

Abbreviations: HRS, hepatorenal syndrome; DF, degrees of freedom; MAP, mean arterial pressure; sCr, serum creatinine; MELD, Model for End-Stage Liver Disease.